Versant Ventures and Biogen completed a $70m investment in Dayra Therapeutics.

Versant Ventures, a healthcare venture capital firm, and Biogen, a biotechnology company, completed a $70m investment in Dayra Therapeutics, a biotechnology research company. “The field of macrocycles is at a new inflection point and is starting to deliver meaningful medicines. Dayra has brought together insights and enablement from Versant’s Frontier Discovery Engine, exceptional leadership with deep macrocycle drug development expertise, and this foundational collaboration with Biogen, putting the company in a very strong position.” Rami Hannoush, Versant and Dayra Venture Partner and acting CEO.